{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:37:33Z","timestamp":1774366653732,"version":"3.50.1"},"reference-count":263,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270690"],"award-info":[{"award-number":["32270690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070671"],"award-info":[{"award-number":["32070671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Inf Sci Syst"],"DOI":"10.1007\/s13755-023-00264-5","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T06:02:02Z","timestamp":1702879322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine"],"prefix":"10.1007","volume":"12","author":[{"given":"Shumin","family":"Ren","sequence":"first","affiliation":[]},{"given":"Jiakun","family":"Li","sequence":"additional","affiliation":[]},{"given":"Juli\u00e1n","family":"Dorado","sequence":"additional","affiliation":[]},{"given":"Alejandro","family":"Sierra","sequence":"additional","affiliation":[]},{"given":"Humbert","family":"Gonz\u00e1lez-D\u00edaz","sequence":"additional","affiliation":[]},{"given":"Aliuska","family":"Duardo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2899-1531","authenticated-orcid":false,"given":"Bairong","family":"Shen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"1","key":"264_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegal","year":"2014","unstructured":"Siegal R, Miller KD, Jemal AJCCJC. Cancer statistics, 2012. CA Cancer J Clin. 2014;64(1):9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"264_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2016.02.002","volume":"40","author":"EE Van Toom","year":"2016","unstructured":"Van Toom EE, Verdone JE, Pienta KJ. Disseminated tumor cells and dormancy in prostate cancer metastasis. Curr Opin Biotechnol. 2016;40:9\u201315.","journal-title":"Curr Opin Biotechnol"},{"issue":"11","key":"264_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0030225","volume":"3","author":"N Beerenwinkel","year":"2007","unstructured":"Beerenwinkel N, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol. 2007;3(11): e225.","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"264_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","volume":"15","author":"W Liu","year":"2009","unstructured":"Liu W, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559\u201365.","journal-title":"Nat Med"},{"issue":"1","key":"264_CR5","doi-asserted-by":"crossref","first-page":"pbac001","DOI":"10.1093\/pcmedi\/pbac001","volume":"5","author":"Y Lin","year":"2022","unstructured":"Lin Y, et al. Multivariate competing endogenous RNA network characterization for cancer microRNA biomarker discovery: a novel bioinformatics model with application to prostate cancer metastasis. Precis Clin Med. 2022;5(1):pbac001.","journal-title":"Precis Clin Med"},{"issue":"10","key":"264_CR6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41585-018-0060-7","volume":"15","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, et al. Landmarks in prostate cancer. Nat Rev Urol. 2018;15(10):627\u201342.","journal-title":"Nat Rev Urol"},{"issue":"8","key":"264_CR7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.aje.a009698","volume":"148","author":"R Etzioni","year":"1998","unstructured":"Etzioni R, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemio. 1998;148(8):775\u201385.","journal-title":"Am J Epidemio"},{"key":"264_CR8","volume":"260","author":"E Zhang","year":"2020","unstructured":"Zhang E, et al. An overview of advances in multi-omics analysis in prostate cancer. Life Sci. 2020;260: 118376.","journal-title":"Life Sci"},{"key":"264_CR9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2021.10.012","volume":"524","author":"NJT del Flores-T\u00e9llez","year":"2022","unstructured":"del Flores-T\u00e9llez NJT, Baena EJCL. Experimental challenges to modeling prostate cancer heterogeneity. Cancer Lett. 2022;524:194\u2013205.","journal-title":"Cancer Lett"},{"issue":"11","key":"264_CR10","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/1878-0261.12568","volume":"13","author":"LT Hoang","year":"2019","unstructured":"Hoang LT, et al. Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer. Mol Oncol. 2019;13(11):2406\u201321.","journal-title":"Mol Oncol"},{"issue":"8","key":"264_CR11","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1002\/jcp.27973","volume":"234","author":"X Luo","year":"2019","unstructured":"Luo X, et al. Integration of metabolomic and transcriptomic data reveals metabolic pathway alteration in breast cancer and impact of related signature on survival. J Cell Physiol. 2019;234(8):13021\u201331.","journal-title":"J Cell Physiol"},{"issue":"2","key":"264_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1534\/genetics.110.120907","volume":"187","author":"BE Stranger","year":"2011","unstructured":"Stranger BE, Stahl EA, Raj TJG. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics. 2011;187(2):367\u201383.","journal-title":"Genetics"},{"issue":"1","key":"264_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imed.2021.06.001","volume":"1","author":"J Dong","year":"2021","unstructured":"Dong J. Intelligent medicine, the wings of global health. Intell Med. 2021;1(1):1\u20132.","journal-title":"Intell Med"},{"issue":"24","key":"264_CR14","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-JJJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532\u201342.","journal-title":"JAMA"},{"issue":"24","key":"264_CR15","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.3390\/ijms21249511","volume":"21","author":"F Fontana","year":"2020","unstructured":"Fontana F, et al. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Mol Sci. 2020;21(24):9511.","journal-title":"Mol Sci"},{"issue":"1","key":"264_CR16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"264_CR17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.prnil.2021.10.001","volume":"10","author":"S Yamada","year":"2022","unstructured":"Yamada S, et al. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. Prostate Int. 2022;10(1):50\u20135.","journal-title":"Prostate Int"},{"issue":"5","key":"264_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271\u201386.","journal-title":"Nat Rev Urol"},{"key":"264_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.09.020","volume":"439","author":"Y Niu","year":"2018","unstructured":"Niu Y, et al. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Lett. 2018;439:47\u201355.","journal-title":"Cancer Lett"},{"issue":"1","key":"264_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/arpa.2019-0124-RA","volume":"144","author":"V Manucha","year":"2020","unstructured":"Manucha V, Henegan J. Clinicopathologic diagnostic approach to aggressive variant prostate cancer. Arch Pathol Lab Med. 2020;144(1):18\u201323.","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"264_CR21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18(10):581\u201396.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"264_CR22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/caac.21391","volume":"67","author":"MK Buyyounouski","year":"2017","unstructured":"Buyyounouski MK, et al. Prostate cancer\u2013major changes in the American Joint Committee on Cancer eight edition staging manual. Cancer J Clin. 2017;67(3):245\u201353.","journal-title":"Cancer J Clin"},{"issue":"6","key":"264_CR23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PPO.0b013e31823b042c","volume":"17","author":"NE Martin","year":"2011","unstructured":"Martin NE, et al. Prognostic determinants in prostate cancer. Cancer J. 2011;17(6):429.","journal-title":"Cancer J"},{"issue":"5","key":"264_CR24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pros.2990050510","volume":"5","author":"JT Isaacs","year":"1984","unstructured":"Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545\u201357.","journal-title":"Prostate"},{"key":"264_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(10)07005-3","volume":"107","author":"KR Lamont","year":"2010","unstructured":"Lamont KR, Tindall DJ. Androgen regulation of gene expression. Adv Cancer Res. 2010;107:137\u201362.","journal-title":"Adv Cancer Res"},{"issue":"3","key":"264_CR26","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365.","journal-title":"Transl Androl Urol"},{"issue":"6","key":"264_CR27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41585-020-0314-z","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. The diverse roles of SPOP in prostate cancer and kidney cancer. Nat Rev Urol. 2020;17(6):339\u201350.","journal-title":"Nat Rev Urol"},{"issue":"24","key":"264_CR28","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1080\/15384101.2017.1388973","volume":"16","author":"X Dai","year":"2017","unstructured":"Dai X, Wang Z, Wei W. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors. Cell Cycle. 2017;16(24):2326\u20139.","journal-title":"Cell Cycle"},{"issue":"2","key":"264_CR29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","volume":"180","author":"J Gerhardt","year":"2012","unstructured":"Gerhardt J, et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol. 2012;180(2):848\u201361.","journal-title":"Am J Pathol"},{"issue":"5","key":"264_CR30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2006.10.032","volume":"127","author":"S-W Kang","year":"2006","unstructured":"Kang S-W, et al. Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell. 2006;127(5):999\u20131013.","journal-title":"Cell"},{"issue":"5","key":"264_CR31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia J, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645\u201351.","journal-title":"Nat Genet"},{"key":"264_CR32","doi-asserted-by":"crossref","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","volume":"534","author":"F Fontana","year":"2022","unstructured":"Fontana F, Anselmi M, Limonta P. Molecular mechanisms and genetic alterations in prostate cancer: from diagnosis to targeted therapy. Cancer Lett. 2022;534:215619.","journal-title":"Cancer Lett"},{"key":"264_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103370","volume":"163","author":"D Tong","year":"2021","unstructured":"Tong D. Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype. Crit Rev Oncol Hematol. 2021;163: 103370.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1\u20132","key":"264_CR34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477852","volume":"85","author":"Y Tolkach","year":"2018","unstructured":"Tolkach Y, Kristiansen GJP. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85(1\u20132):108\u201316.","journal-title":"Pathobiology"},{"issue":"25","key":"264_CR35","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/onc.2010.121","volume":"29","author":"Y Niu","year":"2010","unstructured":"Niu Y, et al. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 2010;29(25):3593\u2013604.","journal-title":"Oncogene"},{"issue":"2","key":"264_CR36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"264_CR37","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/cancers13143607","volume":"13","author":"AD Puranik","year":"2021","unstructured":"Puranik AD, et al. Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer. Cancers. 2021;13(14):3607.","journal-title":"Cancers"},{"issue":"5","key":"264_CR38","first-page":"586","volume":"45","author":"D Hirano","year":"2004","unstructured":"Hirano D, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Oncol. 2004;45(5):586\u201392.","journal-title":"Eur Oncol"},{"issue":"24","key":"264_CR39","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36(24):2492.","journal-title":"J Clin Oncol"},{"issue":"6","key":"264_CR40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani M, et al. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258\u201366.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"264_CR41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011\u201325.","journal-title":"Cell"},{"issue":"5","key":"264_CR42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328.","journal-title":"Cell"},{"issue":"1","key":"264_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13084-7","volume":"10","author":"LF van Dessel","year":"2019","unstructured":"van Dessel LF, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10(1):1\u201313.","journal-title":"Nat Commun"},{"issue":"3","key":"264_CR44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.eururo.2017.08.027","volume":"73","author":"S Ren","year":"2018","unstructured":"Ren S, et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur Urol. 2018;73(3):322\u201339.","journal-title":"Eur Urol"},{"issue":"10","key":"264_CR45","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/pros.23823","volume":"79","author":"J Blackburn","year":"2019","unstructured":"Blackburn J, et al. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: a focus on Africa. Prostate. 2019;79(10):1191\u20136.","journal-title":"Prostate"},{"issue":"2","key":"264_CR46","first-page":"BR61","volume":"15","author":"KN Stamatiou","year":"2009","unstructured":"Stamatiou KN, et al. The phenomenon of multifocality does not affect the biologic behavior of histologic prostate carcinoma. Med Sci Monit. 2009;15(2):BR61\u20133.","journal-title":"Med Sci Monit"},{"issue":"11","key":"264_CR47","first-page":"2362","volume":"100","author":"R Arora","year":"2004","unstructured":"Arora R, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Int J Am Cancer Soc. 2004;100(11):2362\u20136.","journal-title":"Int J Am Cancer Soc"},{"issue":"17","key":"264_CR48","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1158\/0008-5472.CAN-07-2043","volume":"67","author":"R Mehra","year":"2007","unstructured":"Mehra R, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67(17):7991\u20135.","journal-title":"Cancer Res"},{"issue":"6","key":"264_CR49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","volume":"41","author":"M Andreoiu","year":"2010","unstructured":"Andreoiu M, Cheng LJH. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41(6):781\u201393.","journal-title":"Hum Pathol"},{"issue":"2","key":"264_CR50","first-page":"204","volume":"58","author":"H Suzuki","year":"1998","unstructured":"Suzuki H, et al. Interfocal heterogeneity of PTEN\/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998;58(2):204\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"264_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-016-1129-3","volume":"18","author":"K Mundbjerg","year":"2017","unstructured":"Mundbjerg K, et al. Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol. 2017;18(1):1\u201315.","journal-title":"Genome Biol"},{"issue":"9","key":"264_CR52","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41379-020-0525-0","volume":"33","author":"P Dedigama-Arachchige","year":"2020","unstructured":"Dedigama-Arachchige P, et al. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. Mod Pathol. 2020;33(9):1791\u2013801.","journal-title":"Mod Pathol"},{"issue":"1","key":"264_CR53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pros.23914","volume":"80","author":"Z Lu","year":"2020","unstructured":"Lu Z, et al. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. Prostate. 2020;80(1):38\u201350.","journal-title":"Prostate"},{"issue":"11","key":"264_CR54","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","volume":"123","author":"MC Haffner","year":"2013","unstructured":"Haffner MC, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Investig. 2013;123(11):4918\u201322.","journal-title":"J Clin Investig"},{"issue":"4","key":"264_CR55","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/ERC-16-0049","volume":"23","author":"JL Van Etten","year":"2016","unstructured":"Van Etten JL, Dehm SM. Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer. 2016;23(4):R207\u201317.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"264_CR56","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","volume":"47","author":"PC Boutros","year":"2015","unstructured":"Boutros PC, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47(7):736\u201345.","journal-title":"Nat Genet"},{"issue":"3","key":"264_CR57","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks D, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014;8(3):798\u2013806.","journal-title":"Cell Rep"},{"key":"264_CR58","doi-asserted-by":"crossref","unstructured":"Yadav SS et al. Intratumor heterogeneity in prostate cancer. In: Urologic oncology: seminars and original investigations. Amsterdam: Elsevier; 2018.","DOI":"10.1016\/j.urolonc.2018.05.008"},{"issue":"4","key":"264_CR59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","volume":"47","author":"CS Cooper","year":"2015","unstructured":"Cooper CS, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015;47(4):367\u201372.","journal-title":"Nat Genet"},{"issue":"6","key":"264_CR60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gcc.21944","volume":"51","author":"LK Boyd","year":"2012","unstructured":"Boyd LK, et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer. 2012;51(6):579\u201389.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"264_CR61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/labinvest.2010.179","volume":"91","author":"MA Svensson","year":"2011","unstructured":"Svensson MA, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Investig. 2011;91(3):404\u201312.","journal-title":"Lab Investig"},{"issue":"3","key":"264_CR62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/gcc.20948","volume":"51","author":"P Paulo","year":"2012","unstructured":"Paulo P, et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer. 2012;51(3):240\u20139.","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"264_CR63","first-page":"839","volume":"10","author":"C Magi-Galluzzi","year":"1997","unstructured":"Magi-Galluzzi C, et al. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol. 1997;10(8):839\u201345.","journal-title":"Mod Pathol"},{"issue":"1","key":"264_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-020-00139-y","volume":"5","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, et al. Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021;5(1):1\u20138.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"264_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas P, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):1\u201311.","journal-title":"Nat Commun"},{"issue":"5","key":"264_CR66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"264_CR67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/gtmb.2015.1563","volume":"19","author":"SF Terry","year":"2015","unstructured":"Terry SF. Obama\u2019s precision medicine initiative. Genet Test Mol Biomark. 2015;19(3):113.","journal-title":"Genet Test Mol Biomark"},{"issue":"2","key":"264_CR68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/pcmedi\/pbab007","volume":"4","author":"L Shen","year":"2021","unstructured":"Shen L, et al. The fourth scientific discovery paradigm for precision medicine and healthcare: challenges ahead. Precis Clin Med. 2021;4(2):80\u20134.","journal-title":"Precis Clin Med"},{"issue":"4","key":"264_CR69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1109\/MIS.2015.60","volume":"30","author":"S Saria","year":"2015","unstructured":"Saria S, Goldenberg A. Subtyping: What it is and its role in precision medicine. IEEE Intell Syst. 2015;30(4):70\u20135.","journal-title":"IEEE Intell Syst"},{"issue":"6","key":"264_CR70","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/0929867325666180914115416","volume":"26","author":"U Anceschi","year":"2019","unstructured":"Anceschi U, et al. Novel diagnostic biomarkers of prostate cancer: an update. Curr Med Chem. 2019;26(6):1045\u201358.","journal-title":"Curr Med Chem"},{"issue":"10071","key":"264_CR71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815\u201322.","journal-title":"Lancet"},{"issue":"6","key":"264_CR72","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.eururo.2014.01.016","volume":"65","author":"MJ Roobol","year":"2014","unstructured":"Roobol MJ, Schr\u00f6der FH. The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message. Eur Urol. 2014;65(6):1056\u20137.","journal-title":"Eur Urol"},{"issue":"2","key":"264_CR73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","volume":"39","author":"SJCO Saini","year":"2016","unstructured":"Saini SJCO. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol. 2016;39(2):97\u2013106.","journal-title":"Cell Oncol"},{"issue":"11","key":"264_CR74","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/ijms17111784","volume":"17","author":"X Filella","year":"2016","unstructured":"Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17(11):1784.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"264_CR75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315(1):68\u201376.","journal-title":"JAMA"},{"issue":"9","key":"264_CR76","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"264_CR77","first-page":"134","volume":"80","author":"BF Darst","year":"2021","unstructured":"Darst BF, et al. Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk. Eur Oncol. 2021;80(2):134\u20138.","journal-title":"Eur Oncol"},{"issue":"5","key":"264_CR78","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ijc.33584","volume":"149","author":"K Raspin","year":"2021","unstructured":"Raspin K, et al. A rare variant in EZH2 is associated with prostate cancer risk. Int J Cancer. 2021;149(5):1089\u201399.","journal-title":"Int J Cancer"},{"issue":"3","key":"264_CR79","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-410X.2010.09533.x","volume":"107","author":"P Kesarwani","year":"2011","unstructured":"Kesarwani P, et al. Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer. BJU Int. 2011;107(3):471\u20136.","journal-title":"BJU Int"},{"issue":"7","key":"264_CR80","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","volume":"50","author":"FR Schumacher","year":"2018","unstructured":"Schumacher FR, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928\u201336.","journal-title":"Nat Genet"},{"issue":"8","key":"264_CR81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1046","volume":"27","author":"S Benafif","year":"2018","unstructured":"Benafif S, et al. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Biomark Prev. 2018;27(8):845\u201357.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"264_CR82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/ng2022","volume":"39","author":"M Yeager","year":"2007","unstructured":"Yeager M, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645\u20139.","journal-title":"Nat Genet"},{"key":"264_CR83","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2014.00222","volume":"4","author":"V Vlaeminck-Guillem","year":"2014","unstructured":"Vlaeminck-Guillem V, Gillet G, Rimokh RJ. SRC: marker or actor in prostate cancer aggressiveness. Front Oncol. 2014;4:222.","journal-title":"Front Oncol"},{"issue":"1","key":"264_CR84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","volume":"11","author":"R Eeles","year":"2014","unstructured":"Eeles R, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11(1):18\u201331.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"264_CR85","first-page":"8","volume":"13","author":"R Weichselbaum","year":"1995","unstructured":"Weichselbaum R, Hellman S. Oligometastases. Nat Rev Clin Oncol. 1995;13(1):8\u201310.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"264_CR86","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MOU.0000000000000449","volume":"27","author":"GA Joice","year":"2017","unstructured":"Joice GA, et al. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol. 2017;27(6):533\u201341.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"264_CR87","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"264_CR88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(03)01442-1","volume":"58","author":"D Singh","year":"2004","unstructured":"Singh D, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"264_CR89","first-page":"13","volume":"69","author":"V Khoo","year":"2015","unstructured":"Khoo V. Is there another bite of the cherry? The case for radical local therapy for oligometastatic disease in prostate cancer. Eur Oncol. 2015;69(1):13\u20134.","journal-title":"Eur Oncol"},{"issue":"1","key":"264_CR90","first-page":"161","volume":"70","author":"L Evangelista","year":"2016","unstructured":"Evangelista L, et al. New clinical indications for 18F\/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Oncol. 2016;70(1):161\u201375.","journal-title":"Eur Oncol"},{"issue":"24","key":"264_CR91","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1158\/0008-5472.CAN-04-2442","volume":"64","author":"RB Shah","year":"2004","unstructured":"Shah RB, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209\u201316.","journal-title":"Cancer Res"},{"issue":"6","key":"264_CR92","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10585-014-9664-3","volume":"31","author":"A Uppal","year":"2014","unstructured":"Uppal A, et al. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014;31(6):735\u201348.","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"264_CR93","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","volume":"37","author":"B Dhondt","year":"2019","unstructured":"Dhondt B, et al. Discovery and validation of a serum microRNA signature to characterize oligo-and polymetastatic prostate cancer: not ready for prime time. World J Urol. 2019;37(12):2557\u201364.","journal-title":"World J Urol"},{"issue":"12","key":"264_CR94","doi-asserted-by":"crossref","first-page":"e50141","DOI":"10.1371\/journal.pone.0050141","volume":"7","author":"YA Lussier","year":"2012","unstructured":"Lussier YA, et al. Oligo-and polymetastatic progression in lung metastasis (es) patients is associated with specific microRNAs. PLoS ONE. 2012;7(12):e50141.","journal-title":"PLoS ONE"},{"issue":"11","key":"264_CR95","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1200\/JCO.1999.17.11.3438","volume":"17","author":"D Weckermann","year":"1999","unstructured":"Weckermann D, et al. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol. 1999;17(11):3438\u201343.","journal-title":"J Clin Oncol"},{"issue":"2","key":"264_CR96","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","volume":"15","author":"TM Morgan","year":"2009","unstructured":"Morgan TM, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15(2):677\u201383.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"264_CR97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12307-011-0083-6","volume":"4","author":"A Mishra","year":"2011","unstructured":"Mishra A, et al. Homing of cancer cells to the bone. Cancer Microenvironment. 2011;4(3):221\u201335.","journal-title":"Cancer Microenvironment"},{"issue":"4","key":"264_CR98","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","volume":"155","author":"FGJC Giancotti","year":"2013","unstructured":"Giancotti FGJC. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155(4):750\u201364.","journal-title":"Cell"},{"issue":"23","key":"264_CR99","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","volume":"75","author":"AC Yeh","year":"2015","unstructured":"Yeh AC, Ramaswamy S. Mechanisms of cancer cell dormancy\u2014another hallmark of cancer? Cancer Res. 2015;75(23):5014\u201322.","journal-title":"Cancer Res"},{"key":"264_CR100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ddtec.2014.02.002","volume":"11","author":"H-M Lam","year":"2014","unstructured":"Lam H-M, Vessella RL, Morrissey C. The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. Drug Discov Today. 2014;11:41\u20137.","journal-title":"Drug Discov Today"},{"issue":"3","key":"264_CR101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00109-015-1353-4","volume":"94","author":"C Morrissey","year":"2016","unstructured":"Morrissey C, et al. The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med. 2016;94(3):259\u201365.","journal-title":"J Mol Med"},{"issue":"2","key":"264_CR102","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41391-020-00308-x","volume":"24","author":"T Sumiyoshi","year":"2021","unstructured":"Sumiyoshi T, et al. Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(2):310\u201322.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"264_CR103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.euf.2018.11.011","volume":"5","author":"MJ Kucharczyk","year":"2018","unstructured":"Kucharczyk MJ, Gravis G, Niazi T. The biology of oligometastatic prostate cancer: a different beast than polymetastatic prostate cancer. Eur Urol Focus. 2018;5(2):117\u20138.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"264_CR104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15\u201325.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"264_CR105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.currproblcancer.2019.02.001","volume":"43","author":"W Zhang","year":"2019","unstructured":"Zhang W, et al. Controlling nutritional status score: a new prognostic indicator for patients with oligometastatic prostate cancer. Curr Probl Cancer. 2019;43(5):461\u201370.","journal-title":"Curr Probl Cancer"},{"issue":"13","key":"264_CR106","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.3390\/cancers13133278","volume":"13","author":"G Corrao","year":"2021","unstructured":"Corrao G, et al. Exploring miRNA signature and other potential biomarkers for oligometastatic prostate cancer characterization: the biological challenge behind clinical practice. A narrative review. Cancers. 2021;13(13):3278.","journal-title":"Cancers"},{"key":"264_CR107","doi-asserted-by":"crossref","unstructured":"Rubin P, Brasacchio R, Katz A. Solitary metastases: illusion versus reality. In: Seminars in radiation oncology. Amsterdam: Elsevier. 2006.","DOI":"10.1016\/j.semradonc.2005.12.007"},{"issue":"19","key":"264_CR108","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first-and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149.","journal-title":"J Clin Oncol"},{"issue":"1","key":"264_CR109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, et al. Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12(1):1\u201316.","journal-title":"Nat Commun"},{"issue":"9","key":"264_CR110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.5306\/wjco.v11.i9.679","volume":"11","author":"DA Iacobas","year":"2020","unstructured":"Iacobas DA. Powerful quantifiers for cancer transcriptomics. Worl J Clin Oncol. 2020;11(9):679.","journal-title":"Worl J Clin Oncol"},{"issue":"3","key":"264_CR111","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41391-020-00316-x","volume":"24","author":"K Ng","year":"2021","unstructured":"Ng K, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis. 2021;24(3):718\u201324.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"264_CR112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63.","journal-title":"World J Oncol"},{"issue":"9","key":"264_CR113","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5732\/cjc.011.10324","volume":"31","author":"T Kimura","year":"2012","unstructured":"Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012;31(9):421.","journal-title":"Chin J Cancer"},{"issue":"1","key":"264_CR114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/tpj.2011.44","volume":"13","author":"A Schr\u00f6der","year":"2013","unstructured":"Schr\u00f6der A, et al. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomic J. 2013;13(1):12\u201320.","journal-title":"Pharmacogenomic J"},{"issue":"3","key":"264_CR115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/hmg\/ddq498","volume":"20","author":"J Li","year":"2011","unstructured":"Li J, et al. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011;20(3):528\u201340.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"264_CR116","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1758834017719215","volume":"9","author":"N Terada","year":"2017","unstructured":"Terada N, et al. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(8):565\u201373.","journal-title":"Ther Adv Med Oncol"},{"issue":"5\u20136","key":"264_CR117","first-page":"523","volume":"39","author":"JJ Cui","year":"2020","unstructured":"Cui JJ, et al. Mass spectrometry-based personalized drug therapy. Mass Spectrom Rev. 2020;39(5\u20136):523\u201352.","journal-title":"Mass Spectrom Rev"},{"issue":"7","key":"264_CR118","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgg.2021.03.007","volume":"48","author":"F Feng","year":"2021","unstructured":"Feng F, et al. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. J Genet Genomics. 2021;48(7):540\u201351.","journal-title":"J Genet Genomics"},{"issue":"12","key":"264_CR119","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/pharmaceutics12121240","volume":"12","author":"KA Malsagova","year":"2020","unstructured":"Malsagova KA, et al. Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics. 2020;12(12):1240.","journal-title":"Pharmaceutics"},{"issue":"7","key":"264_CR120","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/cells10071644","volume":"10","author":"S Iacobas","year":"2021","unstructured":"Iacobas S, Iacobas DAJC. A personalized genomics approach of the prostate cancer. Cells. 2021;10(7):1644.","journal-title":"Cells"},{"issue":"4","key":"264_CR121","first-page":"137","volume":"40","author":"A Surendiran","year":"2008","unstructured":"Surendiran A, Pradhan S, Adithan C. Role of pharmacogenomics in drug discovery and development. J Pharmcol. 2008;40(4):137.","journal-title":"J Pharmcol"},{"issue":"6","key":"264_CR122","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/10408363.2017.1384446","volume":"54","author":"L Dimitrakopoulos","year":"2017","unstructured":"Dimitrakopoulos L, et al. Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Crit Rev Clin Lab Sci. 2017;54(6):414\u201332.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"264_CR123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5114\/wo.2014.47136","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Wsp\u00f3\u0142czesna Onkologia. 2015;19:68\u201377.","journal-title":"Wsp\u00f3\u0142czesna Onkologia"},{"key":"264_CR124","doi-asserted-by":"crossref","unstructured":"Clough E, Barrett T. The gene expression omnibus database. In: Statistical genomics. New York Springer; 2016. p. 93\u2013110.","DOI":"10.1007\/978-1-4939-3578-9_5"},{"issue":"6","key":"264_CR125","first-page":"1370","volume":"19","author":"J Yan","year":"2018","unstructured":"Yan J, et al. Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. Brief Bioinform. 2018;19(6):1370\u201381.","journal-title":"Brief Bioinform"},{"issue":"1","key":"264_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"L Yang","year":"2017","unstructured":"Yang L, et al. Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. Sci Rep. 2017;7(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"9","key":"264_CR127","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","volume":"2","author":"H Ross-Adams","year":"2015","unstructured":"Ross-Adams H, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine. 2015;2(9):1133\u201344.","journal-title":"EBioMedicine"},{"issue":"4","key":"264_CR128","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.21037\/tcr.2019.07.05","volume":"8","author":"T-H Hsiao","year":"2019","unstructured":"Hsiao T-H, Chiu Y-C, Shao Y-HJ. Multi-omics analysis reveals the BRCA1 mutation and mismatch repair gene signatures associated with survival, protein expression, and copy number alterations in prostate cancer. Transl Cancer Res. 2019;8(4):1279.","journal-title":"Transl Cancer Res"},{"issue":"8","key":"264_CR129","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/annonc\/mdy224","volume":"29","author":"A Kamoun","year":"2018","unstructured":"Kamoun A, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;29(8):1814\u201321.","journal-title":"Ann Oncol"},{"issue":"4","key":"264_CR130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","volume":"166","author":"JM Drake","year":"2016","unstructured":"Drake JM, et al. Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell. 2016;166(4):1041\u201354.","journal-title":"Cell"},{"issue":"3","key":"264_CR131","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","volume":"35","author":"A Sinha","year":"2019","unstructured":"Sinha A, et al. The proteogenomic landscape of curable prostate cancer. Cancer Cell. 2019;35(3):414\u201327.","journal-title":"Cancer Cell"},{"key":"264_CR132","volume":"12","author":"Z Wei","year":"2022","unstructured":"Wei Z, et al. Deep learning-based multi-omics integration robustly predicts relapse in prostate cancer. Front Oncol. 2022;12: 893424.","journal-title":"Front Oncol"},{"issue":"1","key":"264_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-02185-y","volume":"18","author":"MA Kiebish","year":"2020","unstructured":"Kiebish MA, et al. Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer. J Transl Med. 2020;18(1):1\u201310.","journal-title":"J Transl Med"},{"issue":"4","key":"264_CR134","doi-asserted-by":"crossref","first-page":"273","DOI":"10.21873\/cgp.20132","volume":"16","author":"OK Kwon","year":"2019","unstructured":"Kwon OK, et al. Comparative proteome profiling and mutant protein identification in metastatic prostate cancer cells by quantitative mass spectrometry-based proteogenomics. Cancer Genomic Proteomics. 2019;16(4):273\u201386.","journal-title":"Cancer Genomic Proteomics"},{"issue":"5","key":"264_CR135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/metabo9050082","volume":"9","author":"B Gao","year":"2019","unstructured":"Gao B, et al. Multi-omics analyses detail metabolic reprogramming in lipids, carnitines, and use of glycolytic intermediates between prostate small cell neuroendocrine carcinoma and prostate adenocarcinoma. Metabolites. 2019;9(5):82.","journal-title":"Metabolites"},{"issue":"1","key":"264_CR136","doi-asserted-by":"crossref","first-page":"1851950","DOI":"10.1080\/2162402X.2020.1851950","volume":"9","author":"B Vittrant","year":"2020","unstructured":"Vittrant B, et al. Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. Oncoimmunology. 2020;9(1):1851950.","journal-title":"Oncoimmunology"},{"issue":"1","key":"264_CR137","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1074\/mcp.M115.052381","volume":"15","author":"S Ren","year":"2016","unstructured":"Ren S, et al. Integration of metabolomics and transcriptomics reveals major metabolic pathways and potential biomarker involved in prostate cancer. Mol Cell Proteomics. 2016;15(1):154\u201363.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"264_CR138","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12864-019-5457-z","volume":"20","author":"Y Feng","year":"2019","unstructured":"Feng Y, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics. 2019;20(1):146.","journal-title":"BMC Genomics"},{"key":"264_CR139","doi-asserted-by":"crossref","unstructured":"Danckaert W et al. Microbiome and metabolome dynamics during radiotherapy for prostate cancer. Radiother Oncol, 2023: 109950.","DOI":"10.1016\/j.radonc.2023.109950"},{"issue":"9","key":"264_CR140","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/1878-0261.12348","volume":"12","author":"K Murphy","year":"2018","unstructured":"Murphy K, et al. Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. Mol Oncol. 2018;12(9):1513\u201325.","journal-title":"Mol Oncol"},{"key":"264_CR141","doi-asserted-by":"crossref","unstructured":"Meng J et al. Integrated multi\u2010omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clin Transl Med. 2021; 11(12).","DOI":"10.1002\/ctm2.655"},{"issue":"5","key":"264_CR142","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jmcb\/mjab004","volume":"13","author":"X Ye","year":"2021","unstructured":"Ye X, et al. IPPC: an interactive platform for prostate cancer multi-omics data integration and analysis. J Mol Cell Biol. 2021;13(5):383\u20135.","journal-title":"J Mol Cell Biol"},{"key":"264_CR143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PGPM.S167886","volume":"12","author":"S Jeibouei","year":"2019","unstructured":"Jeibouei S, et al. Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics Personalized Med. 2019;12:59\u201373.","journal-title":"Pharmacogenomics Personalized Med"},{"key":"264_CR144","first-page":"112","volume":"1","author":"U Zanger","year":"2010","unstructured":"Zanger U. Pharmacogenetics\u2014challenges and opportunities ahead. Front Pharmacol. 2010;1:112.","journal-title":"Front Pharmacol"},{"key":"264_CR145","volume-title":"Genomic and precision medicine: infectious and inflammatory disease","author":"GS Ginsburg","year":"2019","unstructured":"Ginsburg GS, et al. Genomic and precision medicine: infectious and inflammatory disease. New York: Academic Press; 2019."},{"key":"264_CR146","doi-asserted-by":"crossref","unstructured":"Adam T, Aliferis C. Personalized and precision medicine informatics: a workflow-based view. 2020.","DOI":"10.1007\/978-3-030-18626-5"},{"issue":"5","key":"264_CR147","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/humu.22080","volume":"33","author":"PN Robinson","year":"2012","unstructured":"Robinson PN. Deep phenotyping for precision medicine. Hum Mutat. 2012;33(5):777\u201380.","journal-title":"Hum Mutat"},{"issue":"7576","key":"264_CR148","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/527S14a","volume":"527","author":"CM Delude","year":"2015","unstructured":"Delude CM. Deep phenotyping: the details of disease. Nature. 2015;527(7576):S14\u20135.","journal-title":"Nature"},{"issue":"3","key":"264_CR149","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41571-019-0273-6","volume":"17","author":"JT Yurkovich","year":"2020","unstructured":"Yurkovich JT, et al. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol. 2020;17(3):183\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"264_CR150","first-page":"1903","volume":"1842","author":"MR van der Sijde","year":"2014","unstructured":"van der Sijde MR, Ng A, Fu J. Systems genetics: from GWAS to disease pathways. Biochem Biophys Acta. 2014;1842(10):1903\u20139.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"264_CR151","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrg3575","volume":"15","author":"M Civelek","year":"2014","unstructured":"Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet. 2014;15(1):34\u201348.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"264_CR152","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/cancers14030675","volume":"14","author":"O Golubnitschaja","year":"2022","unstructured":"Golubnitschaja O, et al. Systemic effects reflected in specific biomarker patterns are instrumental for the paradigm change in prostate cancer management: a strategic paper. Cancers. 2022;14(3):675.","journal-title":"Cancers"},{"key":"264_CR153","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704664","volume":"11","author":"S Soares","year":"2021","unstructured":"Soares S, et al. The influence of miRNAs on radiotherapy treatment in prostate cancer\u2014a systematic review. Front Oncol. 2021;11: 704664.","journal-title":"Front Oncol"},{"issue":"1","key":"264_CR154","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/andr.13086","volume":"10","author":"M Konoshenko","year":"2022","unstructured":"Konoshenko M, Laktionov P. The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors. Andrology. 2022;10(1):51\u201371.","journal-title":"Andrology"},{"issue":"2","key":"264_CR155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/andr.12921","volume":"9","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Bryzgunova OE, Laktionov PP. miRNAs and radiotherapy response in prostate cancer. Andrology. 2021;9(2):529\u201345.","journal-title":"Andrology"},{"issue":"6","key":"264_CR156","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers12061550","volume":"12","author":"F Cou\u00f1ago","year":"2020","unstructured":"Cou\u00f1ago F, et al. Clinical applications of molecular biomarkers in prostate cancer. Cancers. 2020;12(6):1550.","journal-title":"Cancers"},{"issue":"3","key":"264_CR157","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ng.332","volume":"41","author":"JF Ayroles","year":"2009","unstructured":"Ayroles JF, et al. Systems genetics of complex traits in Drosophila melanogaster. Nat Genet. 2009;41(3):299\u2013307.","journal-title":"Nat Genet"},{"issue":"39","key":"264_CR158","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1073\/pnas.1213423109","volume":"109","author":"W Huang","year":"2012","unstructured":"Huang W, et al. Epistasis dominates the genetic architecture of Drosophila quantitative traits. Proc Natl Acad Sci USA. 2012;109(39):15553\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"264_CR159","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ng.2411","volume":"44","author":"C Wu","year":"2012","unstructured":"Wu C, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet. 2012;44(10):1090\u20137.","journal-title":"Nat Genet"},{"issue":"9","key":"264_CR160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrg2617","volume":"10","author":"D Quigley","year":"2009","unstructured":"Quigley D, Balmain A. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet. 2009;10(9):651\u20137.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"264_CR161","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.med.0000433056.76699.5d","volume":"20","author":"RF Kushner","year":"2013","unstructured":"Kushner RF, Sorensen KW. Lifestyle medicine: the future of chronic disease management. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):389\u201395.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"264_CR162","first-page":"661","volume":"48","author":"G Egger","year":"2019","unstructured":"Egger G. Development of a lifestyle medicine. Austral J Gener Pract. 2019;48(10):661.","journal-title":"Austral J Gener Pract"},{"issue":"1","key":"264_CR163","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12916-017-0938-x","volume":"15","author":"PM Mutie","year":"2017","unstructured":"Mutie PM, Giordano GN, Franks PW. Lifestyle precision medicine: the next generation in type 2 diabetes prevention? BMC Med. 2017;15(1):171.","journal-title":"BMC Med"},{"issue":"20","key":"264_CR164","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1158\/1078-0432.CCR-13-2394","volume":"20","author":"T Ho","year":"2014","unstructured":"Ho T, et al. Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clin Cancer Res. 2014;20(20):5331\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"264_CR165","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.28423","volume":"134","author":"N Sawada","year":"2014","unstructured":"Sawada N, et al. Alcohol and smoking and subsequent risk of prostate cancer in Japanese men: the Japan Public Health Center-based prospective study. Int J Cancer. 2014;134(4):971\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"264_CR166","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-021-01017-x","volume":"23","author":"CS Langlais","year":"2021","unstructured":"Langlais CS, et al. Post-diagnostic dietary and lifestyle factors and prostate cancer recurrence, progression, and mortality. Curr Oncol Rep. 2021;23(3):37.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"264_CR167","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40279-016-0648-0","volume":"47","author":"RJ Shephard","year":"2017","unstructured":"Shephard RJ. Physical activity and prostate cancer: an updated review. Sports Med. 2017;47(6):1055\u201373.","journal-title":"Sports Med"},{"issue":"4","key":"264_CR168","first-page":"245","volume":"70","author":"CL Rock","year":"2020","unstructured":"Rock CL, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer J Clin. 2020;70(4):245\u201371.","journal-title":"CA: A Cancer J Clin"},{"issue":"6","key":"264_CR169","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2010.31.5226","volume":"29","author":"SA Kenfield","year":"2011","unstructured":"Kenfield SA, et al. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726\u201332.","journal-title":"J Clin Oncol"},{"issue":"7","key":"264_CR170","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdu012","volume":"25","author":"D Schmid","year":"2014","unstructured":"Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25(7):1293\u2013311.","journal-title":"Ann Oncol"},{"issue":"7","key":"264_CR171","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/pon.4732","volume":"27","author":"T Corbett","year":"2018","unstructured":"Corbett T, et al. Exploring cancer survivors\u2019 views of health behaviour change: \u201cWhere do you start, where do you stop with everything?\u201d Psychooncology. 2018;27(7):1816\u201324.","journal-title":"Psychooncology"},{"issue":"1","key":"264_CR172","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00520-021-06404-5","volume":"30","author":"A Lemanska","year":"2022","unstructured":"Lemanska A, et al. Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment. Supportive Care Cancer. 2022;30(1):347\u201358.","journal-title":"Supportive Care Cancer"},{"issue":"4","key":"264_CR173","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","volume":"69","author":"L Bourke","year":"2016","unstructured":"Bourke L, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):693\u2013703.","journal-title":"Eur Urol"},{"issue":"3","key":"264_CR174","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41391-021-00346-z","volume":"24","author":"AM Algotar","year":"2021","unstructured":"Algotar AM, et al. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):903\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"264_CR175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"issue":"1","key":"264_CR176","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jbmr.505","volume":"27","author":"GW Rowland","year":"2012","unstructured":"Rowland GW, et al. Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype. J Bone Miner Res. 2012;27(1):187\u201394.","journal-title":"J Bone Miner Res"},{"key":"264_CR177","unstructured":"CANCER, T.E.O.P., Exercise and Activity for Prostate Cancer. https:\/\/zerocancer.org\/learn\/current-patients\/maintain-qol\/exercise-and-activity\/. Accessed 27 July 2022."},{"issue":"2","key":"264_CR178","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/0284186X.2012.742564","volume":"52","author":"LW Jones","year":"2013","unstructured":"Jones LW, Alfano CM. Exercise-oncology research: past, present, and future. Acta Oncol. 2013;52(2):195\u2013215.","journal-title":"Acta Oncol"},{"key":"264_CR179","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-981-16-9162-1_9","volume-title":"Translational informatics: sports and exercise medicine","author":"M Jiang","year":"2022","unstructured":"Jiang M, Chen Y, Shen B. Exercise guidelines for cancer patients. In: Shen B, editor. Translational informatics: sports and exercise medicine. Singapore: Springer; 2022. p. 177\u2013202."},{"issue":"7","key":"264_CR180","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3042","volume":"34","author":"A Chobot","year":"2018","unstructured":"Chobot A, et al. Obesity and diabetes-Not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7): e3042.","journal-title":"Diabetes Metab Res Rev"},{"issue":"13","key":"264_CR181","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/2047487319884376","volume":"27","author":"V Tuka","year":"2020","unstructured":"Tuka V, Linhart A. Personalised exercise prescription: finding the best for our patients. Eur J Prev Cardiol. 2020;27(13):1366\u20138.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"264_CR182","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(17)30014-1","volume":"5","author":"MC Riddell","year":"2017","unstructured":"Riddell MC, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5(5):377\u201390.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"264_CR183","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","volume":"32","author":"JR Gardner","year":"2014","unstructured":"Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335\u201346.","journal-title":"J Clin Oncol"},{"key":"264_CR184","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3389\/fphys.2019.00843","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, et al. Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: a systematic review and meta-analysis. Front Physiol. 2019;10:843.","journal-title":"Front Physiol"},{"key":"264_CR185","doi-asserted-by":"crossref","unstructured":"Chen Y et al. PCaLiStDB: a lifestyle database for precision prevention of prostate cancer. Database 2020.","DOI":"10.1093\/database\/baz154"},{"issue":"8","key":"264_CR186","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.pmrj.2018.02.006","volume":"10","author":"G Sheill","year":"2018","unstructured":"Sheill G, et al. Considerations for exercise prescription in patients with bone metastases: a comprehensive narrative review. PM R. 2018;10(8):843\u201364.","journal-title":"PM R"},{"issue":"1","key":"264_CR187","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nuf.12296","volume":"54","author":"NA Dasso","year":"2019","unstructured":"Dasso NA. How is exercise different from physical activity? A concept analysis. Nurs Forum. 2019;54(1):45\u201352.","journal-title":"Nurs Forum"},{"issue":"3","key":"264_CR188","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/SPC.0000000000000276","volume":"11","author":"NH Hart","year":"2017","unstructured":"Hart NH, Galv\u00e3o DA, Newton RU. Exercise medicine for advanced prostate cancer. Curr Opin Support Palliat Care. 2017;11(3):247\u201357.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"19","key":"264_CR189","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767\u201377.","journal-title":"N Engl J Med"},{"issue":"3","key":"264_CR190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5152\/dir.2019.19125","volume":"25","author":"SA Harmon","year":"2019","unstructured":"Harmon SA, et al. Artificial intelligence at the intersection of pathology and radiology in prostate cancer. Diagn Intervent Radiol. 2019;25(3):183.","journal-title":"Diagn Intervent Radiol"},{"key":"264_CR191","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109095","volume":"129","author":"A Stanzione","year":"2020","unstructured":"Stanzione A, et al. Prostate MRI radiomics: a systematic review and radiomic quality score assessment. Eur J Radiol. 2020;129: 109095.","journal-title":"Eur J Radiol"},{"issue":"12","key":"264_CR192","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1007\/s00330-020-07027-w","volume":"30","author":"R Cuocolo","year":"2020","unstructured":"Cuocolo R, et al. Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis. Eur Radiol. 2020;30(12):6877\u201387.","journal-title":"Eur Radiol"},{"issue":"13","key":"264_CR193","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/cancers13133318","volume":"13","author":"T Syer","year":"2021","unstructured":"Syer T, et al. Artificial intelligence compared to radiologists for the initial diagnosis of prostate cancer on magnetic resonance imaging: a systematic review and recommendations for future studies. Cancer. 2021;13(13):3318.","journal-title":"Cancer"},{"issue":"6","key":"264_CR194","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/cancers12061606","volume":"12","author":"T Castillo","year":"2020","unstructured":"Castillo T, et al. Automated classification of significant prostate cancer on MRI: a systematic review on the performance of machine learning applications. Cancers. 2020;12(6):1606.","journal-title":"Cancers"},{"issue":"6","key":"264_CR195","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/diagnostics11060959","volume":"11","author":"JJ Twilt","year":"2021","unstructured":"Twilt JJ, et al. Artificial intelligence based algorithms for prostate cancer classification and detection on magnetic resonance imaging: a narrative review. Diagnostics. 2021;11(6):959.","journal-title":"Diagnostics"},{"key":"264_CR196","first-page":"268","volume":"289","author":"U Shah","year":"2022","unstructured":"Shah U, et al. Recent developments in artificial intelligence-based techniques for prostate cancer detection: a scoping review. Stud Health Inform. 2022;289:268\u201371.","journal-title":"Stud Health Inform"},{"issue":"1","key":"264_CR197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13244-022-01199-3","volume":"13","author":"N Sushentsev","year":"2022","unstructured":"Sushentsev N, et al. Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review. Insights Imaging. 2022;13(1):1\u201317.","journal-title":"Insights Imaging"},{"issue":"6","key":"264_CR198","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11547-018-0966-4","volume":"124","author":"H Abdollahi","year":"2019","unstructured":"Abdollahi H, et al. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med (Torino). 2019;124(6):555\u201367.","journal-title":"Radiol Med (Torino)"},{"issue":"1","key":"264_CR199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep26286","volume":"6","author":"G Litjens","year":"2016","unstructured":"Litjens G, et al. Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis. Sci Rep. 2016;6(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"1","key":"264_CR200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","volume":"111","author":"DF Gleason","year":"1974","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58\u201364.","journal-title":"J Urol"},{"issue":"1","key":"264_CR201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-018-0076-7","volume":"2","author":"K Nagpal","year":"2019","unstructured":"Nagpal K, et al. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. NPJ Digital Med. 2019;2(1):1\u201310.","journal-title":"NPJ Digital Med"},{"issue":"8","key":"264_CR202","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41591-019-0508-1","volume":"25","author":"G Campanella","year":"2019","unstructured":"Campanella G, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med. 2019;25(8):1301\u20139.","journal-title":"Nat Med"},{"key":"264_CR203","unstructured":"Bulten W et al. Automated gleason grading of prostate biopsies using deep learning. Lancet Oncol. 2019."},{"issue":"2","key":"264_CR204","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","volume":"21","author":"P Strom","year":"2020","unstructured":"Strom P, Kartasalo K, Olsson HJLO. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 2020;21(2):222\u201332.","journal-title":"Lancet Oncol"},{"issue":"1","key":"264_CR205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-30535-1","volume":"8","author":"E Arvaniti","year":"2018","unstructured":"Arvaniti E, et al. Automated Gleason grading of prostate cancer tissue microarrays via deep learning. Sci Rep. 2018;8(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"4","key":"264_CR206","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-018-0067-4","volume":"21","author":"MJ Donovan","year":"2018","unstructured":"Donovan MJ, et al. Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. Prostate Cancer Prostatic Dis. 2018;21(4):594\u2013603.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"264_CR207","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euf.2021.07.002","volume":"7","author":"K Kartasalo","year":"2021","unstructured":"Kartasalo K, et al. Artificial intelligence for diagnosis and Gleason grading of prostate cancer in biopsies\u2014current status and next steps. Eur Urol Focus. 2021;7(4):687\u201391.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"264_CR208","first-page":"49","volume":"72","author":"E Checcucci","year":"2019","unstructured":"Checcucci E, et al. Artificial intelligence and neural networks in urology: current clinical applications. Italian J Urol Nephrol. 2019;72(1):49\u201357.","journal-title":"Italian J Urol Nephrol"},{"issue":"3","key":"264_CR209","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nm.2323","volume":"17","author":"L Chin","year":"2011","unstructured":"Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17(3):297\u2013303.","journal-title":"Nat Med"},{"issue":"13","key":"264_CR210","first-page":"19","volume":"17","author":"Y Hu","year":"2016","unstructured":"Hu Y, et al. A machine learning approach for the identification of key markers involved in brain development from single-cell transcriptomic data. BMC Genomics. 2016;17(13):19\u201329.","journal-title":"BMC Genomics"},{"issue":"5","key":"264_CR211","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/pr.2015.137","volume":"78","author":"AH Tremoulet","year":"2015","unstructured":"Tremoulet AH, et al. Novel data-mining approach identifies biomarkers for diagnosis of Kawasaki disease. Pediatric Res. 2015;78(5):547\u201353.","journal-title":"Pediatric Res"},{"key":"264_CR212","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ebiom.2018.05.010","volume":"32","author":"Q Hou","year":"2018","unstructured":"Hou Q, et al. RankProd combined with genetic algorithm optimized artificial neural network establishes a diagnostic and prognostic prediction model that revealed C1QTNF3 as a biomarker for prostate cancer. EBioMedicine. 2018;32:234\u201344.","journal-title":"EBioMedicine"},{"key":"264_CR213","doi-asserted-by":"crossref","unstructured":"Chen X et al. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account. 2012.","DOI":"10.1371\/journal.pone.0045178"},{"issue":"202","key":"264_CR214","doi-asserted-by":"crossref","first-page":"202ra122","DOI":"10.1126\/scitranslmed.3006408","volume":"5","author":"S Irshad","year":"2013","unstructured":"Irshad S, et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med. 2013;5(202):202ra122.","journal-title":"Sci Transl Med"},{"issue":"1","key":"264_CR215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/bjc.2011.490","volume":"106","author":"S Larkin","year":"2012","unstructured":"Larkin S, et al. Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer. 2012;106(1):157\u201365.","journal-title":"Br J Cancer"},{"issue":"2","key":"264_CR216","first-page":"1","volume":"21","author":"O Hamzeh","year":"2020","unstructured":"Hamzeh O, et al. Prediction of tumor location in prostate cancer tissue using a machine learning system on gene expression data. BMC Bioinform. 2020;21(2):1\u201310.","journal-title":"BMC Bioinform"},{"issue":"6","key":"264_CR217","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/cancers14061565","volume":"14","author":"Y-L Lai","year":"2022","unstructured":"Lai Y-L, et al. Identification of a steroid hormone-associated gene signature predicting the prognosis of prostate cancer through an Integrative bioinformatics analysis. Cancers. 2022;14(6):1565.","journal-title":"Cancers"},{"issue":"19","key":"264_CR218","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.3390\/cancers13194837","volume":"13","author":"E Chelebian","year":"2021","unstructured":"Chelebian E, et al. Morphological features extracted by AI associated with spatial transcriptomics in prostate cancer. Cancers. 2021;13(19):4837.","journal-title":"Cancers"},{"issue":"1","key":"264_CR219","first-page":"1692","volume":"20","author":"J Ge","year":"2019","unstructured":"Ge J, et al. Picasso: a sparse learning library for high dimensional data analysis in R and Python. J Mach Learn Res. 2019;20(1):1692\u20136.","journal-title":"J Mach Learn Res"},{"issue":"3","key":"264_CR220","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1109\/TBDATA.2019.2937785","volume":"7","author":"F Wen","year":"2019","unstructured":"Wen F, et al. Fast and positive definite estimation of large covariance matrix for high-dimensional data analysis. IEEE Trans Big Data. 2019;7(3):603\u20139.","journal-title":"IEEE Trans Big Data"},{"key":"264_CR221","doi-asserted-by":"crossref","unstructured":"Yang S et al. ET-lasso: a new efficient tuning of lasso-type regularization for high-dimensional data. In: Proceedings of the 25th ACM SIGKDD international conference on knowledge discovery & data mining. 2019.","DOI":"10.1145\/3292500.3330910"},{"issue":"12","key":"264_CR222","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/genes11121493","volume":"11","author":"Y Taguchi","year":"2020","unstructured":"Taguchi Y, Turki TJG. Tensor-decomposition-based unsupervised feature extraction applied to prostate cancer multiomics data. Genes. 2020;11(12):1493.","journal-title":"Genes"},{"issue":"7","key":"264_CR223","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-019-0193-3","volume":"16","author":"SL Goldenberg","year":"2019","unstructured":"Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019;16(7):391\u2013403.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"264_CR224","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21758-3","volume":"8","author":"D Bychkov","year":"2018","unstructured":"Bychkov D, et al. Deep learning based tissue analysis predicts outcome in colorectal cancer. Sci Rep. 2018;8(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"4","key":"264_CR225","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/bib\/bbv078","volume":"17","author":"T Zeng","year":"2016","unstructured":"Zeng T, et al. Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals. Brief Bioinform. 2016;17(4):576\u201392.","journal-title":"Brief Bioinform"},{"issue":"11","key":"264_CR226","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/cancers13112528","volume":"13","author":"T-H Wang","year":"2021","unstructured":"Wang T-H, et al. Biomarker identification through multiomics data analysis of prostate cancer prognostication using a deep learning model and similarity network fusion. Cancers. 2021;13(11):2528.","journal-title":"Cancers"},{"issue":"1","key":"264_CR227","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1109\/TMI.2014.2355175","volume":"34","author":"G Lee","year":"2014","unstructured":"Lee G, et al. Supervised multi-view canonical correlation analysis (sMVCCA): Integrating histologic and proteomic features for predicting recurrent prostate cancer. IEEE Trans Med Imaging. 2014;34(1):284\u201397.","journal-title":"IEEE Trans Med Imaging"},{"issue":"3","key":"264_CR228","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/bib\/bbaa197","volume":"22","author":"R Li","year":"2021","unstructured":"Li R, et al. Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer. Brief Bioinform. 2021;22(3):197.","journal-title":"Brief Bioinform"},{"issue":"3","key":"264_CR229","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00345-019-02899-0","volume":"38","author":"IG Schoots","year":"2020","unstructured":"Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol. 2020;38(3):531\u201345.","journal-title":"World J Urol"},{"issue":"7","key":"264_CR230","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/ijms20071637","volume":"20","author":"DF Osses","year":"2019","unstructured":"Osses DF, Roobol MJ, Schoots IG. Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int J Mol Sci. 2019;20(7):1637.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"264_CR231","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MOU.0000000000000423","volume":"27","author":"JT Kearns","year":"2017","unstructured":"Kearns JT, Lin DW. Prediction models for prostate cancer outcomes: what is the state of the art in 2017? Curr Opin Urol. 2017;27(5):469\u201374.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"264_CR232","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/bioinformatics\/btab850","volume":"38","author":"S Ren","year":"2022","unstructured":"Ren S, et al. CRPMKB: a knowledge base of cancer risk prediction models for systematic comparison and personalized applications. Bioinformatics. 2022;38(6):1669\u201376.","journal-title":"Bioinformatics"},{"key":"264_CR233","doi-asserted-by":"crossref","unstructured":"Dhruba SR, et al. Dimensionality reduction based transfer learning applied to pharmacogenomics databases. In: 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). 2018. IEEE.","DOI":"10.1109\/EMBC.2018.8512457"},{"key":"264_CR234","unstructured":"Lee C-J, Devine B, Tarczy-Hornoch P. A knowledge-based system for intelligent support in pharmacogenomics evidence assessment: ontology-driven evidence representation and retrieval. AMIA Summit Transl Sci Proc. 2017; 175."},{"key":"264_CR235","volume":"128","author":"G Liang","year":"2020","unstructured":"Liang G, et al. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020;128: 110255.","journal-title":"Biomed Pharmacother"},{"key":"264_CR236","doi-asserted-by":"crossref","unstructured":"Alqahtani A. Application of artificial intelligence in discovery and development of anticancer and antidiabetic therapeutic agents. Evid-Based Complement Altern Med 2022.","DOI":"10.1155\/2022\/6201067"},{"issue":"7","key":"264_CR237","doi-asserted-by":"crossref","first-page":"e0219774","DOI":"10.1371\/journal.pone.0219774","volume":"14","author":"AP Lind","year":"2019","unstructured":"Lind AP, Anderson PC. Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties. PLoS ONE. 2019;14(7):e0219774.","journal-title":"PLoS ONE"},{"issue":"1","key":"264_CR238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02088-w","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun. 2018;9(1):1\u201315.","journal-title":"Nat Commun"},{"issue":"16","key":"264_CR239","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1021\/acs.jcim.2c00731","volume":"62","author":"C Santiago","year":"2022","unstructured":"Santiago C, et al. Prediction of antileishmanial compounds: general model, preparation, and evaluation of 2-acylpyrrole derivatives. J Chem Inf Model. 2022;62(16):3928\u201340.","journal-title":"J Chem Inf Model"},{"issue":"23","key":"264_CR240","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.3390\/ijms222313066","volume":"22","author":"V Quevedo-Tumailli","year":"2021","unstructured":"Quevedo-Tumailli V, Ortega-Tenezaca B, Gonz\u00e1lez-D\u00edaz H. IFPTML mapping of drug graphs with protein and chromosome structural networks vs pre-clinical assay information for discovery of antimalarial compounds. Int J Mol Sci. 2021;22(23):13066.","journal-title":"Int J Mol Sci"},{"issue":"42","key":"264_CR241","doi-asserted-by":"crossref","first-page":"27211","DOI":"10.1021\/acsomega.0c03356","volume":"5","author":"A Cabrera-Andrade","year":"2020","unstructured":"Cabrera-Andrade A, et al. Perturbation-Theory Machine Learning (PTML) multilabel model of the ChEMBL dataset of preclinical assays for antisarcoma compounds. ACS Omega. 2020;5(42):27211\u201320.","journal-title":"ACS Omega"},{"key":"264_CR242","doi-asserted-by":"crossref","unstructured":"Nascimento AC, Prud\u00eancio RB, Costa IG. A drug-target network-based supervised machine learning repurposing method allowing the use of multiple heterogeneous information sources. In: Computational methods for drug repurposing. New York: Springer; 2019. p. 281\u2013289.","DOI":"10.1007\/978-1-4939-8955-3_17"},{"issue":"1","key":"264_CR243","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1049\/iet-syb.2018.5094","volume":"14","author":"A Sharma","year":"2020","unstructured":"Sharma A, Rani R. Ensembled machine learning framework for drug sensitivity prediction. IET Syst Biol. 2020;14(1):39\u201346.","journal-title":"IET Syst Biol"},{"key":"264_CR244","doi-asserted-by":"crossref","first-page":"649429","DOI":"10.3389\/fgene.2021.649429","volume":"12","author":"K Manjang","year":"2021","unstructured":"Manjang K, et al. Limitations of explainability for established prognostic biomarkers of prostate cancer. Front Genet. 2021;12:649429.","journal-title":"Front Genet"},{"key":"264_CR245","unstructured":"Shrikumar A, Greenside P, Kundaje A. Learning important features through propagating activation differences. In: International conference on machine learning. 2017. PMLR."},{"issue":"10","key":"264_CR246","doi-asserted-by":"crossref","DOI":"10.1063\/5.0070493","volume":"31","author":"N Frolov","year":"2021","unstructured":"Frolov N, et al. Machine learning evaluates changes in functional connectivity under a prolonged cognitive load. Chaos. 2021;31(10): 101106.","journal-title":"Chaos"},{"key":"264_CR247","doi-asserted-by":"crossref","unstructured":"Ribeiro MT, Singh S, Guestrin C. \u201cWhy should i trust you?\u201d Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining. 2016.","DOI":"10.1145\/2939672.2939778"},{"key":"264_CR248","unstructured":"Ancona M et al. Towards better understanding of gradient-based attribution methods for deep neural networks. 2017."},{"key":"264_CR249","unstructured":"Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inf Process. 2017; 30."},{"issue":"7880","key":"264_CR250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","volume":"598","author":"HA Elmarakeby","year":"2021","unstructured":"Elmarakeby HA, et al. Biologically informed deep neural network for prostate cancer discovery. Nature. 2021;598(7880):348\u201352.","journal-title":"Nature"},{"key":"264_CR251","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105472","volume":"145","author":"S Toledo-Cort\u00e9s","year":"2022","unstructured":"Toledo-Cort\u00e9s S, et al. Grading diabetic retinopathy and prostate cancer diagnostic images with deep quantum ordinal regression. Comput Biol Med. 2022;145: 105472.","journal-title":"Comput Biol Med"},{"issue":"12","key":"264_CR252","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1109\/TKDE.2017.2754499","volume":"29","author":"Q Wang","year":"2017","unstructured":"Wang Q, et al. Knowledge graph embedding: a survey of approaches and applications. IEEE Trans Knowl Data Eng. 2017;29(12):2724\u201343.","journal-title":"IEEE Trans Knowl Data Eng"},{"key":"264_CR253","unstructured":"Kerdjoudj F, Cur\u00e9 O. RDF knowledge graph visualization from a knowledge extraction system. 2015."},{"key":"264_CR254","doi-asserted-by":"crossref","first-page":"112948","DOI":"10.1016\/j.eswa.2019.112948","volume":"141","author":"X Chen","year":"2020","unstructured":"Chen X, Jia S, Xiang Y. A review: knowledge reasoning over knowledge graph. Expert Syst Appl. 2020;141:112948.","journal-title":"Expert Syst Appl"},{"key":"264_CR255","doi-asserted-by":"crossref","unstructured":"Wise C, et al. COVID-19 knowledge graph: accelerating information retrieval and discovery for scientific literature. 2020.","DOI":"10.18653\/v1\/2020.knlp-1.1"},{"key":"264_CR256","doi-asserted-by":"crossref","unstructured":"Saha A, et al. Complex sequential question answering: towards learning to converse over linked question answer pairs with a knowledge graph. In: Proceedings of the AAAI Conference on Artificial Intelligence. 2018.","DOI":"10.1609\/aaai.v32i1.11332"},{"key":"264_CR257","doi-asserted-by":"crossref","first-page":"149220","DOI":"10.1109\/ACCESS.2020.3016142","volume":"8","author":"A Ait-Mlouk","year":"2020","unstructured":"Ait-Mlouk A, Jiang L. KBot: a knowledge graph based chatBot for natural language understanding over linked data. IEEE Access. 2020;8:149220\u201330.","journal-title":"IEEE Access"},{"issue":"1","key":"264_CR258","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.29","volume":"2","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. Prostate cancer management with lifestyle intervention: from knowledge graph to Chatbot. Clin Transl Discov. 2022;2(1): e29.","journal-title":"Clin Transl Discov"},{"issue":"1","key":"264_CR259","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"Q Ye","year":"2021","unstructured":"Ye Q, et al. A unified drug\u2013target interaction prediction framework based on knowledge graph and recommendation system. Nat Commun. 2021;12(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"8","key":"264_CR260","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1109\/TKDE.2020.3028705","volume":"34","author":"Q Guo","year":"2020","unstructured":"Guo Q, et al. A survey on knowledge graph-based recommender systems. IEEE Trans Knowl Data Eng. 2020;34(8):3549\u201368.","journal-title":"IEEE Trans Knowl Data Eng"},{"key":"264_CR261","doi-asserted-by":"crossref","first-page":"176668","DOI":"10.1109\/ACCESS.2019.2958002","volume":"7","author":"M Barros","year":"2019","unstructured":"Barros M, Moitinho A, Couto FM. Using research literature to generate datasets of implicit feedback for recommending scientific items. IEEE Access. 2019;7:176668\u201380.","journal-title":"IEEE Access"},{"issue":"8","key":"264_CR262","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1109\/JBHI.2022.3173558","volume":"26","author":"D Sousa","year":"2022","unstructured":"Sousa D, Couto FM. Biomedical relation extraction with knowledge graph-based recommendations. IEEE J Biomed Health Inform. 2022;26(8):4207\u201317.","journal-title":"IEEE J Biomed Health Inform"},{"issue":"3","key":"264_CR263","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/bib\/bbac140","volume":"23","author":"X Su","year":"2022","unstructured":"Su X, et al. Attention-based knowledge graph representation learning for predicting drug-drug interactions. Brief Bioinform. 2022;23(3):140.","journal-title":"Brief Bioinform"}],"container-title":["Health Information Science and Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13755-023-00264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13755-023-00264-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13755-023-00264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T08:22:34Z","timestamp":1733214154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13755-023-00264-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":263,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1007\/s13755-023-00264-5","relation":{},"ISSN":["2047-2501"],"issn-type":[{"value":"2047-2501","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"6"}}